Intellect Neurosciences, Inc. to Present at OneMedForum

^{Published on 2011-12-14 06:41:48 - Market Wire}
 

Intellect Neurosciences, Inc. to Present at OneMedForum -- NEW YORK, Dec. 14, 2011 /PRNewswire/ --

[ ]

[ Download image ]

NEW YORK, Dec. 14, 2011 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCPK: ILNS) announces that Dr. Daniel G. Chain, chairman and CEO will be presenting at the 10TH Annual BIO Investor Forum.  Hosted by OneMedPlace, a virtual community that connects emerging companies seeking capital, distribution, and visibility with investors and strategic partners, OneMedForum features emerging private and public healthcare companies. The meeting will take place January 9-12 at the Francis Drake Hotel in San Francisco, Calif. Dr. Chain will be presenting on January 11th at 11:45 a.m. in the Windsor Room.  Dr. Chain will also attend the JP Morgan Healthcare Conference being held from January 11-14 at the Westin St. Francis Hotel.

(Logo: [ http://photos.prnewswire.com/prnh/20111214/NY22484LOGO ] )

"Intellect Neurosciences is at the forefront of Alzheimer's research, with a rich pipeline and intellectual property portfolio and licensed products in late-stage clinical development," said Dr. Chain.  "We look forward to the opportunity to interact with the investor community at both OneMedForum and the JP Morgan Investor Conference to discuss our progress in building our IP and technology portfolio, and our development of ground-breaking treatments for Alzheimer's and other devastating neurodegenerative diseases."

About Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer's disease, and other neurodegenerative diseases especially focused on proteinopathies. Intellect's pipeline includes small neuroprotective molecules and neoepitope-based immunotherapy approaches including monoclonal antibodies and vaccines targeting beta amyloid and abnormal tau proteins.

The company is currently developing three separate platform technologies: ANTISENILIN® is Intellect's Alzheimer's beta amyloid monoclonal antibody platform technology which underlies several products in advanced clinical development and is licensed to major pharmaceutical companies. The company's RECALL-VAX technology is a proprietary Alzheimer's vaccine with therapeutic and prophylactic potential. The company's CONJUMAB-A platform is based on antibody drug conjugates with potential applications to treat a broad spectrum of proteinopathies including Alzheimer's disease, Early-Onset Familial Alzheimer's disease, cerebral angiopathy, age-related macular degeneration, glaucoma and traumatic brain injury.

IN-N01-OX2 is the company's most advanced internal candidate, a humanized monoclonal antibody targeting beta amyloid conjugated to a naturally occurring small drug molecule with potent neuroprotective properties. Thus, IN-N01-OX2, incorporates combined features of the ANTISENILIN and CONJUMAB-A platform technologies. The company recently licensed OX1 a small molecule multimodal antioxidant to ViroPharma, Inc. for Friedreich's Ataxia and other neurodegenerative diseases. For more information, please visit [ www.intellectns.com ].

About OneMedForum

Founded in 2008, [ OneMedForum ] is a biannual event held in San Francisco and in New York. OneMedForum creates a platform for emerging companies to connect with strategic partners and investors.  For more about OneMedForum SF 2012 visit [ www.onemedforum.com ].

Safe Harbor Statement Regarding Forward-Looking Statements:

The statements in this release and oral statements made by representatives of Intellect relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Intellect's Annual Report on Form 10-K (file no. 333-128226), filed on October 13, 2011, and in our Quarterly Report on Form 10-Q/A for the quarterly period ended September 30, 2011, filed on November 10, 2011.

Contact:
Jules Abraham
JQA Partners, LLC
917-885-7378
[ jabraham@jqapartners.com ]

SOURCE Intellect Neurosciences, Inc.

RELATED LINKS
[ http://www.intellectns.com ]
[ http://www.onemedforum.com ]